Data issue put Leo Pharma in the Danish Medicines Agency's crosshairs in 2021

During a good clinical practice inspection at Leo Pharma last year, the Danish Medicines Agency struggled to gain access to data related to two clinical eczema studies. The next step would have been ”regulatory action.”

Photo: Leo Pharma/PR

Leo Pharma didn’t exactly welcome a good clinical practice (GCP) inspection by the Danish Medicines Agency with open arms last year and would have faced ”regulatory action” if it failed to hand over documents pertaining to clinical studies of eczema treatments tralokinumab and delgocitinib, industry media Dagens Pharma reports.

The media has seen the agency’s inspection report from March 2021, which said the agency couldn’t gain access to information about certain computer systems that were used to handle study data, which is one of the essential elements of the clinical process, Dagens Pharma writes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs